Expert Opinion on Biological Therapy最新文献_第9页

Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis 老年类风湿关节炎患者使用生物疗法的注意事项

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-13 DOI: 10.1080/14712598.2024.2404521

Noor Nooh, May N Lwin, Christopher Edwards

引用次数: 0

Mosunetuzumab for the treatment of follicular lymphoma. 用于治疗滤泡性淋巴瘤的莫苏尼珠单抗。

IF 4.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-11 DOI: 10.1080/14712598.2024.2404079

Caterina Labanca,Enrica Antonia Martino,Ernesto Vigna,Antonella Bruzzese,Francesco Mendicino,Paola De Luca,Eugenio Lucia,Virginia Olivito,Valentina Fragliasso,Antonino Neri,Fortunato Morabito,Massimo Gentile

{"title":"Mosunetuzumab for the treatment of follicular lymphoma.","authors":"Caterina Labanca,Enrica Antonia Martino,Ernesto Vigna,Antonella Bruzzese,Francesco Mendicino,Paola De Luca,Eugenio Lucia,Virginia Olivito,Valentina Fragliasso,Antonino Neri,Fortunato Morabito,Massimo Gentile","doi":"10.1080/14712598.2024.2404079","DOIUrl":"https://doi.org/10.1080/14712598.2024.2404079","url":null,"abstract":"INTRODUCTIONFollicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history, and a median survival of approximately 18-20 years. The advent of anti-CD20 monoclonal antibodies has changed the FL therapeutic algorithm, with an increase in progression-free survival. T-cell-dependent bispecific antibodies (BsAbs) represent an emerging drug class against FL.AREAS COVEREDIn this review, we selected papers from the principal databases (PubMed, Medline, Medscape, ASCO, ESMO) between January 2021 and June 2024, using the keywords 'mosunetuzumab' and 'follicular lymphoma' to provide an overview of mosunetuzumab-axgb, a pioneering BsAb. Its mechanism of action, efficacy, safety and future perspectives were analyzed.EXPERT OPINIONmosunetuzumab grants a directing T-cell mediated cytotoxicity and allows a step-up dosing that reduces adverse events, such as cytokine release syndrome, with promising tolerability. At the same time, it improves outcomes in the evolving landscape of FL management, even in post-CAR-T FL patients. Prognostic factors and targetable mechanisms of resistance need to be explored.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":"1 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma. 免疫疗法治疗转移性和局部晚期胃食管腺癌的现状和前景。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1080/14712598.2024.2395921

Izuma Nakayama, Kohei Shitara

{"title":"The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma.","authors":"Izuma Nakayama, Kohei Shitara","doi":"10.1080/14712598.2024.2395921","DOIUrl":"10.1080/14712598.2024.2395921","url":null,"abstract":"Introduction: Immunochemotherapy with PD-1 blockade has been established as the current standard first-line therapy for patients with mGEA. Reviewing the history of clinical trials offers valuable insight into the evolution of immune oncology in mGEA, paving the way for future advancements in this field.Areas covered: This review summarizes the findings of previous clinical trials related to immunotherapy for patients with GEA in the metastatic and locally advanced setting. We also introduce ongoing clinical trials to address the current challenging issues in clinical practice.Expert opinion: In general, GEA exhibits intermediate immunogenic characteristics with heterogeneous expressions, and responders to anti-PD-(L)1 therapy are mostly enriched to patients with specific genomic profiles such as MSI-H, high PD-L1 expression, high TMB, and EBV-associated type. Co-administration with anti-angiogenic agents or simultaneous blockade of immune checkpoint molecules is being explored to offer benefit of immunotherapy for more patients. We hope that CLDN18.2 and upcoming targets like FGFR2b will complement the treatment niche of immunotherapy in the field of mGEA. Bispecific antibodies, antibody drug conjugates, CAR-T, and vaccine are anticipated to enhance efficacy and expand the scope of immunotherapy.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"903-915"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors. 克服 CAR-T 细胞疗法在抗原异质性实体瘤中的效率限制。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/14712598.2024.2399141

Astero Klampatsa

引用次数: 0

How comparative studies can inform treatment decisions for Crohn's disease. 比较研究如何为克罗恩病的治疗决策提供依据。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.1080/14712598.2024.2389985

Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, Luca Brandaleone, Giacomo Marcozzi, Giulia Migliorisi, Alessandro Armuzzi

{"title":"How comparative studies can inform treatment decisions for Crohn's disease.","authors":"Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, Luca Brandaleone, Giacomo Marcozzi, Giulia Migliorisi, Alessandro Armuzzi","doi":"10.1080/14712598.2024.2389985","DOIUrl":"10.1080/14712598.2024.2389985","url":null,"abstract":"Introduction: As new therapies for the treatment of Crohn's disease (CD) are approved, there is an increasing need for evidence that clarifies their positioning and sequencing.Areas covered: Comparative effectiveness research (CER) aims to inform physicians' decisions when they choose which intervention (drug or treatment strategy) to administer to their patients. Pragmatic head-to-head trials represent the best tools for CER, but only a few have been published in the IBD field. Network meta-analyses can point toward the superiority of one drug over another, but they do not reflect everyday clinical practice. Finally, real-world evidence complements that coming from head-to-head trials and network meta-analyses, assessing the real-life effectiveness of therapeutic interventions.Expert opinion: There is insufficient evidence to create a definitive therapeutic algorithm for CD, but some general considerations can be made. Anti-TNF-α agents seemingly represent the most 'sustainable' first-line choice, considering benefit-harm ratio and costs; vedolizumab, ustekinumab, and risankizumab may be considered as first-line choice when safety issues become prominent. In the event of pharmacodynamic failure, out-of-class swap is to be preferred - possibly with anti-IL23p19 as the best option, with unclear data regarding upadacitinib positioning; a second anti-TNF-α could be considered, as a second choice, after pharmacokinetic failure.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"955-972"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis. 基于干细胞的肌萎缩性脊髓侧索硬化症临床前和治疗方法的现状和新途径。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-23 DOI: 10.1080/14712598.2024.2392307

Letizia Mazzini, Fabiola De Marchi, Leonora Buzanska, Antonia Follenzi, Joel Clinton Glover, Maurizio Gelati, Ivan Lombardi, Margherita Maioli, Fatima Mesa-Herrera, Dinko Mitrečić, Cristina Olgasi, Augustas Pivoriūnas, Rosario Sanchez-Pernaute, Chiara Sgromo, Marzena Zychowicz, Angelo Vescovi, Daniela Ferrari

{"title":"Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis.","authors":"Letizia Mazzini, Fabiola De Marchi, Leonora Buzanska, Antonia Follenzi, Joel Clinton Glover, Maurizio Gelati, Ivan Lombardi, Margherita Maioli, Fatima Mesa-Herrera, Dinko Mitrečić, Cristina Olgasi, Augustas Pivoriūnas, Rosario Sanchez-Pernaute, Chiara Sgromo, Marzena Zychowicz, Angelo Vescovi, Daniela Ferrari","doi":"10.1080/14712598.2024.2392307","DOIUrl":"10.1080/14712598.2024.2392307","url":null,"abstract":"Introduction: Cell therapy development represents a critical challenge in amyotrophic lateral sclerosis (ALS) research. Despite more than 20 years of basic and clinical research, no definitive safety and efficacy results of cell-based therapies for ALS have been published.Areas covered: This review summarizes advances using stem cells (SCs) in pre-clinical studies to promote clinical translation and in clinical trials to treat ALS. New technologies have been developed and new experimental in vitro and animal models are now available to facilitate pre-clinical research in this field and to determine the most promising approaches to pursue in patients. New clinical trial designs aimed at developing personalized SC-based treatment with biological endpoints are being defined.Expert opinion: Knowledge of the basic biology of ALS and on the use of SCs to study and potentially treat ALS continues to grow. However, a consensus has yet to emerge on how best to translate these results into therapeutic applications. The selection and follow-up of patients should be based on clinical, biological, and molecular criteria. Planning of SC-based clinical trials should be coordinated with patient profiling genetically and molecularly to achieve personalized treatment. Much work within basic and clinical research is still needed to successfully transition SC therapy in ALS.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"933-954"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical management and innovation in fracture non-union. 骨折不愈合的临床管理与创新。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1080/14712598.2024.2391491

C Siverino, W-J Metsemakers, R Sutter, E Della Bella, M Morgenstern, J Barcik, M Ernst, M D'Este, A Joeris, M Chittò, P Schwarzenberg, M Stoddart, N Vanvelk, G Richards, E Wehrle, F Weisemann, S Zeiter, C Zalavras, P Varga, T F Moriarty

{"title":"Clinical management and innovation in fracture non-union.","authors":"C Siverino, W-J Metsemakers, R Sutter, E Della Bella, M Morgenstern, J Barcik, M Ernst, M D'Este, A Joeris, M Chittò, P Schwarzenberg, M Stoddart, N Vanvelk, G Richards, E Wehrle, F Weisemann, S Zeiter, C Zalavras, P Varga, T F Moriarty","doi":"10.1080/14712598.2024.2391491","DOIUrl":"10.1080/14712598.2024.2391491","url":null,"abstract":"Introduction: With the introduction and continuous improvement in operative fracture fixation, even the most severe bone fractures can be treated with a high rate of successful healing. However, healing complications can occur and when healing fails over prolonged time, the outcome is termed a fracture non-union. Non-union is generally believed to develop due to inadequate fixation, underlying host-related factors, or infection. Despite the advancements in fracture fixation and infection management, there is still a clear need for earlier diagnosis, improved prediction of healing outcomes and innovation in the treatment of non-union.Areas covered: This review provides a detailed description of non-union from a clinical perspective, including the state of the art in diagnosis, treatment, and currently available biomaterials and orthobiologics.Subsequently, recent translational development from the biological, mechanical, and infection research fields are presented, including the latest in smart implants, osteoinductive materials, and in silico modeling.Expert opinion: The first challenge for future innovations is to refine and to identify new clinical factors for the proper definition, diagnosis, and treatment of non-union. However, integration of in vitro, in vivo, and in silico research will enable a comprehensive understanding of non-union causes and correlations, leading to the development of more effective treatments.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"973-991"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process. 美国食品和药物管理局批准用于治疗杜氏肌营养不良症的 delandistrogene moxeparvovec-rokl：对证据和监管程序的批判性审查。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-20 DOI: 10.1080/14712598.2024.2394477

Mehul Bhattacharyya, Larry E Miller, Anna L Miller, Ruemon Bhattacharyya

引用次数: 0

The future of aptamers in cancer diagnosis, prognosis and treatment. 适配体在癌症诊断、预后和治疗中的未来。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-03 DOI: 10.1080/14712598.2024.2399148

Jazmine Arévalo, Adrian Gabriel Torres

引用次数: 0

IL-17 inhibitors in axial spondyloarthritis. An overview. 轴性脊柱关节炎中的 IL-17 抑制剂。综述。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.1080/14712598.2024.2394472

Eric Toussirot, Renaud Felten

{"title":"IL-17 inhibitors in axial spondyloarthritis. An overview.","authors":"Eric Toussirot, Renaud Felten","doi":"10.1080/14712598.2024.2394472","DOIUrl":"10.1080/14712598.2024.2394472","url":null,"abstract":"Introduction: The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spondyloarthritis (axSpA).Areas covered: This literature review provides an update on the role of IL-17 in the pathogenesis of axSpA, efficacy and safety from clinical trials and real-life studies on the use of IL17i in axSpA. We also review the impact of extra-musculoskeletal manifestations on the decision to treat with IL17i and the efficacy of IL17i on structural progression.Expert opinion: There are still some unanswered questions concerning the use of IL-17i in axSpA in clinical practice such as their respective place in the management of axSpA compared to TNFα inhibitors (TNFi). Their main differences rely on their specific efficacy in extra-articular manifestations such as psoriasis, uveitis, and inflammatory bowel diseases leading to the choice of the best treatment in a given patient. Regarding their real impact on structural progression, the rate of progression under IL-17i appears to be low and presumably similar to TNFi. One final question is the advantage of blocking the two IL-17 isoforms A and F compared to the single inhibition of IL-17A.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"917-932"},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0